NeuroSense Therapeutics Ltd. has secured a new U.S. patent covering the use of its investigational combination therapy PrimeC for Alzheimer’s disease, extending intellectual property protection until 2043. The patent, No. 12,527,768, grants exclusivity over compositions containing an anti-inflammatory drug and a Dicer activator—a mechanistic profile matching PrimeC’s pairing of celecoxib and ciprofloxacin—for the treatment of neurodegenerative conditions. The milestone arrives as the company prepares to release clinical and biomarker data from its RoAD (Research on Alzheimer’s Disease) proof-of-concept study in the first quarter of 2026.

Why the new IP extends beyond legal coverage and becomes a strategic asset

For small and mid-sized biotechnology companies, intellectual property can often function as a currency—both for internal asset valuation and external partnering discussions. By securing U.S. exclusivity through 2043, NeuroSense Therapeutics now has a far more attractive strategic runway for PrimeC. The newly issued patent builds upon its prior intellectual property in amyotrophic lateral sclerosis and broadens coverage to include Alzheimer’s disease, a much larger and commercially intense market.

This also gives the company leverage in potential licensing negotiations or development partnerships. While intellectual property does not substitute for robust clinical results, it often becomes a necessary predicate for Big Pharma engagement, particularly in neurodegenerative disease where trial timelines are long and investment risks are high. Analysts following the neurodegeneration space suggest this kind of exclusivity could be particularly useful if PrimeC shows moderate but reproducible efficacy in a well-defined subpopulation of Alzheimer’s patients.

Dual-mechanism strategy aligns with Alzheimer’s pipeline shifts but still faces validation hurdles

PrimeC’s therapeutic hypothesis—that a combination of ciprofloxacin and celecoxib can modulate inflammatory cascades, RNA regulation, iron homeostasis, and neurodegeneration—reflects a broader shift in the Alzheimer’s drug development community. The failures of monotherapies targeting amyloid beta have opened the door for multi-mechanism approaches that integrate inflammation, protein clearance, and neuroprotection.

However, clinicians emphasize that the mechanistic promise of combination therapies must be matched by rigorous biomarker validation. This is especially true for a candidate like PrimeC that does not directly engage amyloid or tau, the two hallmarks traditionally associated with disease progression. The upcoming RoAD study readout is therefore not just about tolerability or safety—it will be scrutinized for evidence of disease-relevant target engagement.

In the Alzheimer’s space, failure to show biomarker correlation often stalls programs regardless of safety. The example of simufilam, which struggled to gain credibility despite a plausible mechanism, underscores the importance of biomarker alignment with clinical endpoints. For PrimeC, the question is not whether a dual-target strategy is appealing—it is whether the specific targets being modulated are sufficiently validated and meaningfully affected in humans.

What the RoAD study is expected to reveal—and why its interpretation may shape future regulatory direction

According to disclosures from NeuroSense Therapeutics, the RoAD study was designed as a proof-of-concept trial, focusing on safety and exploratory biomarker assessment in patients with Alzheimer’s disease. Top-line results indicated a favorable safety profile. However, the value of the study will hinge on two data dimensions: first, changes in biological markers associated with disease progression, and second, any early signal of cognitive or functional impact.

Industry observers note that biomarkers such as neurofilament light chain (NfL), inflammatory cytokines, and markers of synaptic degeneration may be included in the analysis. These will be assessed for signal magnitude, directionality, and consistency across treated cohorts. Any deviation from baseline trends that supports disease modification—rather than transient physiological effects—would represent a significant development in the program’s lifecycle.

Equally important will be how the U.S. Food and Drug Administration responds to the use of these biomarkers as potential surrogates. While accelerated approval pathways have historically accepted amyloid plaque reduction as a viable marker, there is no precedent yet for combination therapies using non-amyloid, non-tau biomarkers as primary endpoints. NeuroSense Therapeutics will need to build a compelling case if it intends to rely on these signals for regulatory advancement.

The ALS parallel: Why cross-indication insights could de-risk or distract PrimeC’s Alzheimer’s path

NeuroSense Therapeutics originally developed PrimeC as a candidate for amyotrophic lateral sclerosis (ALS), where the drug has advanced through multiple studies. The ALS formulation uses the same two active pharmaceutical ingredients—celecoxib and ciprofloxacin—combined into an extended-release oral formulation. There are clear synergies in drug development, manufacturing, and biomarker strategy across both indications.

However, Alzheimer’s disease presents a different clinical and regulatory landscape. ALS programs are typically faster-moving, smaller, and judged by more urgent functional endpoints. Alzheimer’s trials, by contrast, often span years and face higher statistical hurdles for cognition and global function. Even if PrimeC achieves signal detection in ALS, it does not guarantee translatability in Alzheimer’s—particularly when patient populations, disease kinetics, and regulatory expectations diverge sharply.

Nevertheless, having a second indication in development may reduce risk perception among investors, who often reward pipeline redundancy. If the Alzheimer’s program falters, NeuroSense Therapeutics can continue to advance PrimeC in ALS with the added benefit of learnings from the broader biomarker and safety datasets. But success in Alzheimer’s would be significantly more transformative from a commercial standpoint, given the size of the global dementia treatment market.

Safety profile may offer a competitive edge—if long-term tolerability is confirmed

One potential advantage of PrimeC lies in its oral formulation and use of already-approved drugs. Unlike monoclonal antibodies such as lecanemab or donanemab, which require intravenous infusion and often carry risks of amyloid-related imaging abnormalities (ARIA), PrimeC could offer a more accessible and better-tolerated option—especially for community-based care settings.

However, each of the component drugs has known long-term safety concerns. Celecoxib has been associated with cardiovascular risks, especially when used chronically at higher doses. Ciprofloxacin belongs to the fluoroquinolone class, which carries black box warnings for tendon rupture, CNS effects, and potential mitochondrial toxicity. While NeuroSense’s extended-release formulation may minimize systemic exposure, regulators and clinicians will likely demand long-term safety studies before endorsing wide use, particularly in older adults.

If the RoAD data reinforce the favorable safety profile observed in top-line results, that could distinguish PrimeC in a field often constrained by risk-benefit tradeoffs. But safety alone, absent efficacy, rarely carries a program through development in Alzheimer’s.

Commercial pathway remains uncertain given generic components and payer dynamics

From a market access perspective, NeuroSense Therapeutics will need to establish clear therapeutic differentiation to justify reimbursement for PrimeC. Both ciprofloxacin and celecoxib are generic drugs, available at low cost. While the fixed-dose combination and novel release profile are proprietary, payers may challenge the pricing model unless efficacy is clearly superior to generic equivalents administered separately.

Moreover, in Alzheimer’s disease, cost-effectiveness scrutiny is intensifying. Recent debates around the pricing of amyloid-targeting drugs, including aducanumab, have raised the bar for what constitutes reimbursable innovation. NeuroSense will need to show that PrimeC not only modifies disease trajectory but also does so with meaningful impact on caregiver burden, institutionalization rates, or long-term cognitive function.

Without strong health economic data, adoption may be limited to clinical trial settings or out-of-pocket markets. This underscores why the upcoming RoAD biomarker and functional data will influence not just regulatory discussions but payer modeling assumptions as well.

PrimeC’s future rests on evidence, not patents

The issuance of a 17-year U.S. patent for PrimeC in Alzheimer’s disease gives NeuroSense Therapeutics a valuable legal asset. But in an environment where regulators, payers, and prescribers demand clear evidence of efficacy, mechanism, and safety, intellectual property will not substitute for data. With RoAD results imminent, the company stands at a critical juncture.

Should the trial reveal credible biomarker movement and early functional benefit, NeuroSense could find itself fielding partnership interest and building a case for Phase 2 development under an expedited framework. If the signals are weak or inconsistent, however, the program may revert to a longer path centered on ALS or alternative neurological indications.

Ultimately, the strength of PrimeC’s Alzheimer’s proposition will be judged not by what is written in a patent, but by what is seen in the clinic.

  Alzheimer’s disease, celecoxib, ciprofloxacin, combination therapy, neurodegenerative diseases, NeuroSense Therapeutics, PrimeC, RNA dysregulation, RoAD study